ORPHA:2789
Lateral meningocele syndrome
Also known as: Lehman syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
231
73.6th percentile
Trials
0
Interventional, condition-specific
Researchers
1,097
Distinct authors in sample
Gene link
NOTCH3
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic neurological disorder characterized by multiple lateral meningoceles, distinctive facial dysmorphism (including hypertelorism, downslanting palpebral fissures, posteriorly rotated ears, micrognathia, and high, narrow palate, among others), and skeletal abnormalities (e. g. vertebral anomalies, wormian bones, short stature, and scoliosis). Multiple additional features may present, such as conductive hearing impairment, , and connective tissue and urogenital abnormalities. Cognition is usually normal.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007537
- MeSH:C537878
- OMIM:130720
- UMLS:C1851710
Additional Mondo synonyms (1)
lateral meningocele syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — NOTCH3
- LiteraturePresent
231 matched papers (148 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (NOTCH3).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
231
231 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
231 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
148 in the last 10 years · medium confidence · 73.6th percentile (publications denominator)
Phrase hits: 231 · MeSH hits: 0
Who's working on it?
1,097
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Canalis E16 papers · 2026
Department of Orthopaedic Surgery, UConn Health, Farmington, Connecticut 06030 canalis@uchc.edu.
Papers in Europe PMC - 02Schilling L9 papers · 2026
UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut 06030.
Papers in Europe PMC - 03Yu J9 papers · 2026
Department of Orthopaedic Surgery, UConn Health, Farmington, Connecticut 06030.
Papers in Europe PMC - 04
- 05Li Y4 papers · 2024
Department of Haematology, Zhujiang Hospital of Southern Medical University, Guangzhou, P.R. China.
Papers in Europe PMC - 06Castori M3 papers · 2018
Department of Medical Genetics, San Camillo-Forlanini Hospital, Sapienza University of Rome and San Camillo - Forlanin, Rome, Italy.
Papers in Europe PMC - 07Gripp KW3 papers · 2015
Division of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Pennsylvania 19104-4399, USA.
Papers in Europe PMC - 08Yamamoto S3 papers · 2022
Department of Molecular and Human Genetics, Baylor College of Medicine (BCM), Houston, TX, USA. yamamoto@bcm.edu.
Papers in Europe PMC - 09Zanotti S3 papers · 2021
Departments of Orthopaedic Surgery and Medicine and the UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut 06030.
Papers in Europe PMC - 10Zhang Q3 papers · 2026
Neural Systems Group, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
General rare disease registries you may be eligible for
These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.
- NCT01793168·RECRUITING·Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Conditions: Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence · Cornelia De Lange Syndrome
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Lateral meningocele syndrome" OR "Lehman syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lateral meningocele syndrome" OR "Lehman syndrome" OR "NOTCH3"
Recall-expansion terms: NOTCH3
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (231) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-26T21:12:27.947Z